Sign up Australia
Proactive Investors - Run By Investors For Investors

SAGE Therapeutics skyrockets as second depression drug in as many months aces mid-stage trial

Sage’s SAGE-217 drug was statistically significant in reducing the symptoms of major depressive disorder compared to a placebo
depressed woman
The company looks set to add the best of US$2.5bn to its market value on the back of the results

Shares in SAGE Therapeutics Inc (NASDAQ:SAGE) skyrocketed in premarket trading on Thursday after the biotech’s depression drug aced a mid-stage trial.

In a statement, the Massachusetts-based group said 64% of patients taking its SAGE-217 drug saw their major depressive disorder (MDD) go into remission within 15 days of treatment.

Patients were assessed on a scale that rated the severity of their depression symptoms such as mood, feelings of guilt, suicidal thoughts and insomnia.

Shares gained 79.9% to US$165.30 in premarket trade on Thursday, leaving the firm on course to add around US$2.5bn to its market value.

“These very encouraging data suggest the potential of SAGE-217 in the treatment of MDD as well as other mood-related disorders that we may pursue,” said Jeff Jonas, Sage’s chief executive.

“The positive activity and safety findings of SAGE-217 in MDD support advancing the program into later stage clinical development and we will work with the FDA to determine next steps in the further development of SAGE-217.”

It’s Sage’s second success in as many months. Back in November the company said its brexanolone postpartum depression drug met its main goal in two late-stage studies, pacing the way for the first FDA-approved treatment for the disorder.

According to Reuters, Sage won’t seek to partner with another company for the phase III trial.

In the regular session, shares added over 76% to US$162.22 each.

View full SAGE profile View Profile

SAGE Therapeutics Timeline

Related Articles

pills
November 08 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use